Dynamic viral markers predict treatment response in hepatitis B

For individuals living with chronic hepatitis B, achieving a “functional cure” – meaning the loss of hepatitis B surface antigen (HBsAg) – has proven challenging with existing treatments like pegylated interferon (PEG-IFN). A recent study, analyzing data from 38 studies encompassing 6,179 patients, sought to identify which virological markers best predict both functional cure and loss of the hepatitis B e antigen (HBeAg).

Identifying Predictors of Treatment Success

Researchers systematically reviewed studies published up to November 2023 in PubMed, Embase, the Cochrane Library, and Web of Science. The goal was to pinpoint which virological measurements could most accurately forecast a positive response to PEG-IFN therapy. Predictive effectiveness was assessed using a summary receiver operating characteristic curve.

Key Findings on Functional Cure

The analysis revealed that a decline in HBsAg levels at week 24 of treatment demonstrated the strongest ability to predict functional cure, with an area under the receiver operating characteristic curve (AUROC) of 0.89 and a sensitivity of 0.88. Baseline HBsAg levels also showed a comparable AUROC (0.86) and the highest specificity (0.79). Both of these markers proved significantly more effective than baseline measurements of hepatitis B core-related antigen and hepatitis B virus (HBV) RNA.

Did You Know? The study analyzed data from 6,179 patients across 38 different studies to identify the best predictors of treatment success.

Predicting HBeAg Loss

The study also identified indicators for predicting HBeAg loss. On-treatment HBV RNA levels, HBeAg levels, and changes in these levels over time were found to be the most reliable predictors of HBeAg loss.

Expert Insight: Identifying reliable predictors of treatment response is crucial for optimizing the use of PEG-IFN in chronic hepatitis B. This research suggests focusing on HBsAg decline during treatment and baseline HBsAg levels to better identify patients most likely to benefit from this therapy.

What Could Happen Next

These findings could lead to more personalized treatment strategies for chronic hepatitis B. Clinicians may increasingly focus on monitoring HBsAg levels during the first 24 weeks of PEG-IFN therapy to assess a patient’s likelihood of achieving a functional cure. Further research could explore whether adjusting treatment regimens based on these markers could improve overall outcomes. It is also possible that new therapies will be developed that specifically target HBsAg to enhance functional cure rates.

Frequently Asked Questions

What is a functional cure in hepatitis B?

A functional cure is defined as the loss of hepatitis B surface antigen (HBsAg).

What is PEG-IFN?

PEG-IFN is pegylated interferon, a treatment used for chronic hepatitis B.

Which marker had the greatest ability to predict functional cure?

HBsAg decline at week 24 had the greatest discriminative ability for predicting functional cure.

How might a better understanding of these predictive markers impact the future of hepatitis B treatment?